← Back to Clinical Trials
Recruiting NCT05751408

NCT05751408 Technical Evaluation of Commercial IMUs Within Clinical Gait Analysis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05751408
Status Recruiting
Phase
Sponsor Roessingh Research and Development
Condition Gait Analysis
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2023-01-25
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
gait analysis using 3D (Vicon) and IMU (Movella)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2023-01-25 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A standard clinical gait analysis consists of observing walking with video (2D) or advanced equipment (VICON 3D). This 3D method provides detailed information about the gait pattern, but is time-consuming in implementation and data analysis. There are commercial 3D systems on the market that are used in healthy individuals and in sports. These so-called Inertial Measurement Units (IMUs) may also be suitable for use in the clinic. In this research protocol, the aim is to test the usability of commercial sensors and technically compare them with standard clinical 3D gait analysis in adult patients with a neurological disorder.

Eligibility Criteria

Subjects referred for clinical gait analysis at Roessingh Centre for Rehabilition in Enschede, the Netherlands: Inclusion Criteria: * Disorders affecting walking, including amongst others stroke, traumatic brain injury, MS, incomplete spinal cord injury, CP, Spina Bifida, neuromuscular diseases * age minimum 18 years * Viosca score minimum 2; meaning minimal independent walking ability indoors * increased fall risk or increased effort of walking because of: 1) decreased stability during stance; and/or 2) decreased foot clearance during swing; and/or 3) not able to walk on bare feet because of equinovarus; and/or 4) fatigue during walking because of compansatory strategies. Exclusion Criteria: * subjects referred for clinical gait analysis because of problems other than stiff knee gait or foot surgery * severe deficits in communication, memory and understanding at such a level that it would affect instructions during the measurements

Contact & Investigator

Central Contact

C Nikamp, PhD

✉ c.nikamp@rrd.nl

📞 +31880875777

Principal Investigator

C Nikamp, PhD

PRINCIPAL INVESTIGATOR

Roessingh Research and Development

Frequently Asked Questions

Who can join the NCT05751408 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Gait Analysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05751408 currently recruiting?

Yes, NCT05751408 is actively recruiting participants. Contact the research team at c.nikamp@rrd.nl for enrollment information.

Where is the NCT05751408 trial being conducted?

This trial is being conducted at Enschede, Netherlands.

Who is sponsoring the NCT05751408 clinical trial?

NCT05751408 is sponsored by Roessingh Research and Development. The principal investigator is C Nikamp, PhD at Roessingh Research and Development. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology